Skip to main content

Design Therapeutics, Inc.

DSGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001807120

No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Design Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of DSGN: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders9395+2
Shares34.5M34.5M−37.9K (−0.1%)
Value$116.4M$259.7M+$143.4M (+123.2%)

New holders (14)

Institutions that held Design Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to DSGN in Q3 2025
InstitutionSharesValue% of portfolio
Ra Capital Management, L.P.475,699$3.58M0.04%
Millennium Management LLC68,823$518.2K0.00%
DLD Asset Management, LP50,000$376.5K0.05%
HRT Financial LP31,903$240.0K0.00%
Sphera Funds Management Ltd.21,918$165.0K0.04%
XTX Topco Ltd11,868$89.4K0.00%
MetLife Investment Management10,320$77.7K0.00%
Point72 Asia (Singapore) Pte. Ltd.5,702$42.9K0.01%
California State Teachers Retirement System1,969$14.8K0.00%
GAMMA Investing LLC443$3.34K0.00%
Optiver Holding B.V.328$2.47K0.00%
SRS Capital Advisors, Inc.194$1.46K0.00%
Versant Capital Management, Inc71$5350.00%
Larson Financial Group LLC3$230.00%

Sold out (12)

Institutions that held Design Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.